Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Drug

Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review

Fineline Cube Mar 6, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...

Company Drug

Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study

Fineline Cube Mar 6, 2023

China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully...

Company Deals

PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices

Fineline Cube Mar 6, 2023

PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of...

Company Deals R&D

HKUST and PhIRDA Sign MoU to Establish Innovation Centers

Fineline Cube Mar 4, 2023

The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and...

Policy / Regulatory

China Releases Blue Book on Medical Insurance Fund Supervision

Fineline Cube Mar 3, 2023

The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book...

Policy / Regulatory

NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines

Fineline Cube Mar 3, 2023

The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...

Company Deals

ClinChoice Acquires Cromsource to Expand Global CRO Footprint

Fineline Cube Mar 3, 2023

Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l.,...

Company Drug

Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment

Fineline Cube Mar 3, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from...

Company Deals

Echo Biotech Secures Series A++ Funding for Exosomes Drug Development

Fineline Cube Mar 3, 2023

Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi...

Company Medical Device

AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL

Fineline Cube Mar 3, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion...

Company Drug

CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma

Fineline Cube Mar 3, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...

Policy / Regulatory

National VBP Tender Round 8 to Be Held in Hainan with 40 Drugs Bidding

Fineline Cube Mar 3, 2023

The National Allied Procurement Office has released a notification regarding the Round 8 of the...

Company Deals

TinKer Bio Raises Series A+ Funding for Microfluidic Chip Expansion

Fineline Cube Mar 3, 2023

China-based Hangzhou TinKer BioTechnology Co., Ltd, a leading microfluidic chip technology platform company, has reportedly...

Company Drug

OcuMension Therapeutics Initiates Phase II Study for Dry Eye Treatment OT-202

Fineline Cube Mar 3, 2023

Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the initiation of a randomized, double-blind,...

Company Deals

Hexin Medical Technology Raises Series A Funding for Radionuclide Therapy

Fineline Cube Mar 3, 2023

Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised...

Company Deals

Shanghai Pharmaceuticals Partners with Baiyun District for Health Initiative

Fineline Cube Mar 3, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has entered into a strategic cooperation agreement...

Company Deals

TandemAI Secures $35M Series A to Expand Drug Discovery Platform

Fineline Cube Mar 3, 2023

TandemAI, a technology firm with operations in New York, San Diego, and China, has successfully...

Company Drug

Merck Reports 12.9% Sales Growth in 2022 Annual Report

Fineline Cube Mar 3, 2023

German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...

Policy / Regulatory

NHSA Releases Guidelines on Drug Procurement and Pricing Management

Fineline Cube Mar 2, 2023

The National Healthcare Security Administration (NHSA) has released a notification regarding provincial centralized procurement and...

Company Deals

Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib

Fineline Cube Mar 2, 2023

Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase...

Posts pagination

1 … 594 595 596 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.